Journal
ACTA HAEMATOLOGICA
Volume 134, Issue 4, Pages 255-262Publisher
KARGER
DOI: 10.1159/000430980
Keywords
Chronic lymphocytic leukemia; Programmed death 1 ligand; Microenvironment; Thalidomide
Categories
Funding
- Foundation for Polish Science [FNP FOCUS 01/08]
- Ministry of Science and Higher Education [IUVENTUS PLUS MNISW IP2011014171]
- Medical University of Lublin [DS462]
Ask authors/readers for more resources
Background: The programmed death 1 (PD-1) receptor pathway is responsible for the negative regulation of both T and B lymphocytes upon activation of these cells. There is growing evidence that chronic lymphocytic leukemia (CLL) cells exploit the PD-1 ligand (PD-L1) to resist antitumor immune reactions and maintain their survival by shaping their own microenvironment. Methods: We used a quantitative RT-PCR method to analyze PD-L1 gene expression in bone marrow and peripheral blood mononuclear cells, representing the proliferation and accumulation compartments of CLL. Results: PD-L1 expression was found to be significantly higher in 112 CLL patients than in controls. Levels of PD-L1 expression in bone marrow and peripheral blood were comparable and showed a positive correlation. Furthermore, expression of PD-L1 strongly correlated with expression of PD-1 receptor in mononuclear cells from the same compartment, and was not affected by incubation with immunomodulatory drug thalid-omide. Conclusion: PD-L1 expression is shared between CLL cells localized in distinct disease compartments, demonstrating that PD-1/PD-L1 a universal target for therapy. (C) 2015 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available